(
FINANCIAL HIGHLIGHTS
- Operating costs (MSEK 6.7) well under control
- Cash reserves at year-end (MSEK 13.6) enough to finance completion of Tourette study
-
Strong balance sheet due to conversion of loan in
May 2022
R&D HIGHLIGHTS
Recruitment completed: patient recruitment to Phase IIa study in Tourette completed in
Extensive preclinical study published: on 6 October Asarina Pharma announced the publication of a comprehensive new preclinical study in the Neurobiology of Stress, the fourth in a series of four. Results increase the Translatability of
Last Patient Last Visit: On
Topline results for the Study remain expected to be released at the end of
CEO STATEMENT
CEO
Read the full CEO Statement here: https://asarinapharma.com/investors/financial-reports/
For further information, please contact:
Peter Nordkild, CEO
Phone: +45 25 47 16 46
E-mail: peter.nordkild@asarinapharma.com
ABOUT
We are a Swedish biotech company developing Sepranolone for allopregnanolone-induced stress- and compulsivity-driven disorders. Our product pipeline is built on over 40 years of research into allopregnanolone-related neurological disorders. With our new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) we aim to deliver a new generation of safe, efficacious drugs for neurological conditions from Tourette syndrome to Obsessive Compulsive Disorder that still lack safe, efficacious pharmaceutical treatments.
https://news.cision.com/asarina-pharma/r/asarina-pharma-ab--publ--releases-year-end-report-2022,c3723710
https://mb.cision.com/Main/17069/3723710/1877140.pdf
https://mb.cision.com/Public/17069/3723710/a3abe4d9c6b83714.pdf
(c) 2023 Cision. All rights reserved., source